Budesonide oral gel - Amzell
Latest Information Update: 06 Sep 2024
At a glance
- Originator Bazell Pharma
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eosinophilic oesophagitis
Most Recent Events
- 30 Apr 2024 Amzell withdraws a phase I/II BESIDE trial for Eosinophilic oesophagitis (In adults, In the elderly) (PO, Gel) due to business reasons (NCT05214599)
- 30 May 2022 Preclinical trials in Eosinophilic oesophagitis in Netherlands (PO)
- 24 May 2022 Amzell plans a phase I/II BESIDE trial for Eosinophilic oesophagitis (In adults, In the elderly) (PO, Gel) in January 2023 (NCT05214599)